Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

被引:230
|
作者
McNutt, Markey C.
Lagace, Thomas A.
Horton, Jay D. [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA
[2] Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA
关键词
D O I
10.1074/jbc.C700095200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proprotein convertase subtilisin/kexin type 9 (PCSK9), a member of the proteinase K subfamily of subtilases, promotes internalization and degradation of low density lipoprotein receptors (LDLRs) after binding the receptor on the surface of hepatocytes. PCSK9 has autocatalytic activity that releases the prodomain at the N terminus of the protein. The prodomain remains tightly associated with the catalytic domain as the complex transits the secretory pathway. It is not known whether enzymatic activity is required for the LDLR-reducing effects of PCSK9. Here we expressed the prodomain together with a catalytically inactive protease domain in cells and purified the protein from the medium. The ability of the catalytically inactive PCSK9 to bind and degrade LDLRs when added to culture medium of human hepatoma HepG2 cells at physiological concentrations was similar to that seen using wild-type protein. Similarly, a catalytic-dead version of a gain-of-function mutant, PCSK9(D374Y), showed no loss of activity compared with a catalytically active counterpart; both proteins displayed similar to 10-fold increased activity in degradation of cell surface LDLRs compared with wild-type PCSK9. We conclude that the ability of PCSK9 to degrade LDLRs is independent of catalytic activity and suggest that PCSK9 functions as a chaperone to prevent LDLR recycling and/or to target LDLRs for lysosomal degradation.
引用
收藏
页码:20799 / 20803
页数:5
相关论文
共 50 条
  • [41] Identification of a Small Peptide That Inhibits PCSK9 Protein Binding to the Low Density Lipoprotein Receptor
    Zhang, Yingnan
    Eigenbrot, Charles
    Zhou, Lijuan
    Shia, Steven
    Li, Wei
    Quan, Clifford
    Tom, Jeffrey
    Moran, Paul
    Di Lello, Paola
    Skelton, Nicholas J.
    Kong-Beltran, Monica
    Peterson, Andrew
    Kirchhofer, Daniel
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (02) : 942 - 955
  • [42] A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor
    Yamamoto, Taichi
    Lu, Christine
    Ryan, Robert O.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (07) : 5464 - 5470
  • [43] Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
    Johns, Douglas G.
    Campeau, Louis-Charles
    Banka, Puja
    Bautmans, An
    Bueters, Tjerk
    Bianchi, Elisabetta
    Branca, Danila
    Bulger, Paul G.
    Crevecoeur, Inne
    Ding, Fa-Xiang
    Garbaccio, Robert M.
    Guetschow, Erik D.
    Guo, Yan
    Ha, Sookhee N.
    Johnston, Jennifer M.
    Josien, Hubert
    Kauh, Eunkyung A.
    Koeplinger, Kenneth A.
    Kuethe, Jeffrey T.
    Lai, Eseng
    Lanning, Christine L.
    Lee, Anita Y. H.
    Li, Li
    Nair, Anilkumar G.
    O'Neill, Edward A.
    Stoch, S. Aubrey
    Thaisrivongs, David A.
    Tucker, Thomas J.
    Vachal, Petr
    van Dyck, Kristien
    Vanhoutte, Frederic P.
    Volckaert, Bram
    Wolford, Dennis G.
    Xu, Andy
    Zhao, Tian
    Zhou, Dan
    Zhou, Susan
    Zhu, Xiaohong
    Zokian, Hratch J.
    Walji, Abbas M.
    Wood, Harold B.
    CIRCULATION, 2023, 148 (02) : 144 - 158
  • [44] The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis
    Davignon, Jean
    Dubuc, Genevieve
    Seidah, Nabil G.
    CURRENT ATHEROSCLEROSIS REPORTS, 2010, 12 (05) : 308 - 315
  • [45] Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
    Della Badia, Laura A.
    Elshourbagy, Nabil A.
    Mousa, Shaker A.
    PHARMACOLOGY & THERAPEUTICS, 2016, 164 : 183 - 194
  • [46] Epigenetic silencing of PCSK9 enables durable reduction of low-density lipoprotein cholesterolAtherosclerosis
    Elisa Martini
    Nature Cardiovascular Research, 2025, 4 (4): : 347 - 347
  • [47] PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity
    Guijarro, Carlos
    JAMA CARDIOLOGY, 2017, 2 (10) : 1168 - +
  • [48] Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain
    Strom, Thea Bismo
    Holla, Oystein L.
    Tveten, Kristian
    Cameron, Jamie
    Berge, Knut Erik
    Leren, Trond P.
    MOLECULAR GENETICS AND METABOLISM, 2010, 101 (01) : 76 - 80
  • [49] The Influence of PCSK9 Polymorphisms on Serum Low-Density Lipoprotein Cholesterol and Risk of Atherosclerosis
    Jean Davignon
    Geneviève Dubuc
    Nabil G. Seidah
    Current Atherosclerosis Reports, 2010, 12 : 308 - 315
  • [50] Bokbunja extracts enhance low-density lipoprotein (LDL) receptor expression via attenuation of proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression and stimulates LDL uptake in HepG2
    Song, K.
    Kim, Y.
    Kim, Y.
    Lee, H.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26